Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-03-14, 10:25:37 | version 1.49.03
Contact Dr. rer. nat. Peter Loskill Phone +49 711 970-3531 peter.loskill@igb.fraunhofer.de Funding We would like to thank the Fraunhofer-Gesellschaft for funding the project “Organ-on-a-chip systems for high-throughput screening” within the Fraunhofer Attract program. 2 500 μm 3 to obtain cell types and tissues that have been dificult or impossible to isolate from primary biopsies. hiPS cells can be cryopreserved and expanded, making them far better suited for industrial applications that require reproducible and stan- dardized models. In contrast to embryonic stem cells, the use of hiPS cells is not ethically problematic. Application Organ-on-a-chip systems are envisioned to be primarily used for eficacy and toxicity testing during the preclinical screen- ing of drugs. Additional applications exist in almost every area where animal experiments are in use, such as biomedical basic research and the cosmetic industry, where there is a great demand for alternative methods because the EU will ban the import of all cosmetics tested on animals. Another promising ield of application is personalized medicine. This area is still immature, but it has great long-term potential. 1 Microphysiological fat-on-a-chip system. 2 Fluorescence-stained human adipocytes for fat-on-a-chip systems. 3 Humane iPS-derived cardiomyocytes along a microstructured iber. 6 5